Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues

Bioconjugate Chemistry

Volumn 15, Issue 4, 2004, Pages 814-823

  Aronov, Olga ^a   Horowitz, Aviva T ^b   Gabizon, Alberto ^b   Fuertes, Miguel A ^c   Pérez, José Manuel ^c   Gibson, Dan ^a,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DISEASES; DNA; ETHYLENE GLYCOL; POLYOLS; PROTEINS; TARGETED DRUG DELIVERY;

ANTICANCER DRUG; CANCER CELLS; CARBOPLATIN; EFFICIENT DRUG DELIVERY; LOCALIZING AGENTS; LOW MOLECULAR WEIGHT; NUCLEAR DNA; NUCLEAR LOCALIZATION SIGNAL; PLATINUM DRUGS; THREE-LEVEL;

POLYETHYLENE GLYCOLS;

CARBOPLATIN; CELL NUCLEUS DNA; CISPLATIN; DRUG CARRIER; MACROGOL; MACROGOL CARBOPLATIN CONJUGATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONJUGATE; CYTOTOXICITY; DNA ADDUCT; DNA BINDING; DRUG ACTIVATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; INTERNALIZATION; NUCLEAR LOCALIZATION SIGNAL; PROTEIN LOCALIZATION;

EID: 3242745979     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0499331     Document Type: Article

References (35)

1. Lokich, J. (2001) What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? Cancer Invest. 19, 756-760.
2. Lokich, J., and Anderson, N. (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. 9, 13-21.
3. Cohen, S. M., and Lippard, S. J. (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 67, 93-130.
4. Brabec, V. (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog. Nucleic Acid Res. Mol. Biol. 71, 1-68.
5. Fuertes, M. A., Alonso, C., and Perez, J. M. (2003) Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103, 645-662.
6. Perez, R. P. (1998) Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 34, 1535-1542.
7. Kelland, L. R. (1994) The molecular basis of cisplatin sensitivity/resistance. Eur. J. Cancer 30A, 725-727. (1)
8. Widder, K. J., Senyei, A. E., and Ranney, D. F. (1979) Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv. Pharmacol. Chemother. 16, 213-271.
9. Langer, R. (1998) Drug delivery and targeting. Nature 392, 5-10.
10. Aronov, O., Horowitz, A. T., Gabizon, A., and Gibson, D. (2003) Folate-targeted PEG as a potential carrier for carboplatin analogues. Synthesis and in vitro studies. Bioconjugate Chem. 14, 563-574.
11. Takakura, Y., and Hashida, M. (1996) Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 13, 820-831.
12. Zalipsky, S. (1995) Chemistry of Polyethylene-Glycol Conjugates with Biologically-Active Molecules. Adv. Drug Delivery Rev. 16, 157-182.
13. Wang, S., and Low, P. S. (1998) Folate-mediated targeting of antineoplastic drugs imaging agents, and nucleic acids to cancer cells. J. Controlled Release 53, 39-48.
14. Sudimack, J., and Lee, R. J. (2000) Targeted drug delivery via the folate receptor. Adv. Drug Delivery Rev. 41, 147-162.
15. Castino, R., Demoz, M., and Isidoro, C. (2003) Destination 'lysosome': a target organelle for tumour cell killing? J. Mol. Recognit. 16, 337-348.
16. Green, M., and Loewenstein, P. M. (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179-1188.
17. Joliot, A., Pernelle, C., Deagostini-Bazin, H., and Prochiantz, A. (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. U.S.A. 88, 1864-1868.
18. Pipkorn, R., Waldeck, W., and Braun, K. (2003) Synthesis and application of functional peptides as cell nucleus-directed molecules in the treatment of malignant diseases. J. Mol. Recognit. 16, 240-247.
19. Marks, T. A., Woodman, R. J., Geran, R. I., Billups, L. H., and Madison, R. M. (1977) Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents. Cancer Treat. Rep. 61, 1459-1470.
20. Gabizon, A., Horowitz, A. T., Goren, D., Tzemach, D., Mandelbaum-Shavit, F., et al. (1999) Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjugate Chem. 10, 289-298.
21. Kelland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., and Harrap, K. R. (1993) Preclinical antitumor evaluation of bis-acetatoammine-dichloro-cyclohexy-lamine platinum(IV): an orally active platinum drug. Cancer Res. 53, 2581-2586.
22. Loh, S. Y., Mistry, P., Kelland, L. R., Abel, G., and Harrap, K. R. (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) am-mine/amine complexes. Br. J. Cancer 66, 1109-1115.
23. Goddard, P. M., Orr, R. M., Valenti, M. R., Barnard, C. F., Murrer, B. A., Kelland L. R., and Harrap, K. R. (1996) Novel trans-platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumors. Anticancer Res. 16, 33-38.
24. Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. (1987) Characterization of a cis-diamminedichloroplatinum(II)- resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47, 414-418.
25. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589-601
26. Miller, S. A., Dykes, D. D., and Polesky, H. F.(1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
27. Barnham, K. J., Djuran, M. I., Murdoch, P. S., Ranford, J. D., and Sadler, P. J. (1996) Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. Inorg. Chem. 35, 1065-1072.
28. 2 Complexes Linked to Anthraquinone Intercalators. J. Med. Chem. 34, 414-420.
29. Gibson, D., Binyamin, I., Haj, M., Ringel, I., Ramu, A., et al. (1997) Anthraquinone intercalators as carrier molecules for second-generation platinum anticancer drugs. Eur. J. Med. Chem. 32, 823-831.
30. Fisher, D. M., Fenton, R. R., and Aldrich-Wright, J. R. (2003) Platinum(II) intercalators as potential anti-cancer agents. J. Inorg. Biochem. 96, 131-131.
31. Baruah, H., and Bierbach, U. (2003) Unusual intercalation of acridin-9-ylthiourea into the 5′-GA/TC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate. Nucleic Acids Res. 31, 4138-4146.
32. Palmer, B. D., Lee, H. H., Johnson, P., Baguley, B. C., Wickham, G., et al. (1990) DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine. J. Med. Chem. 33, 3008-3014.
33. Natarajan, G., Malathi, R., and Holler, E. (1999) Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem. Pharmacol. 58, 1625-1629.
34. Blommaert, F. A., van Dijk-Knijnenburg, H. C., Dijt, F. J., den Engelse, L., Baan, R. A., Berends, F., and Fichtinger-Schepman, A. M. (1995) Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34, 8474-8480.
35. Guo, Z. J., Hambley, T. W., Murdoch, P. D., Sadler, P. J., and Frey, U. (1997) Chelate-ring-opened adducts of Pt(en)-(Me-Mal-O,O′) (en equals ethane-1,2-diamine, Me-Mal equals 2-methylmalonate) with methionine derivatives: Relevance to the biological activity of platinum anticancer agents. J. Chem. Soc., Dalton Trans. 469-478.